Processing your request


please wait...

Case Page

 

Case Status:    ONGOING    
On or around 08/22/2019 (Ongoing date of last review)

Filing Date: August 02, 2019

According to the Complaint, Vical is a company historically focused on research and development of biopharmaceutical products for prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development.

This action stems from a proposed transaction announced on June 3, 2019, pursuant to which Vical Incorporated will merge with Brickell Biotech, Inc.

On June 2, 2019, Vical’s Board of Directors caused Vical to enter into an agreement and plan of merger with Brickell. Following the consummation of the Proposed Transaction, Brickell’s stockholders will own approximately 60% of the combined company, and Vical’s stockholders will own approximately 40% of the combined company.

On July 12, 2019, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction, which scheduled a stockholder vote on the Proposed Transaction for August 30, 2019. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on August 26, 2019. A related case continues under Docket 19-CV-07528 in the Southern District of New York.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: VICL
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 19-CV-01457
JUDGE: Hon. Judge Colm F. Connolly
DATE FILED: 08/02/2019
CLASS PERIOD START: 06/03/2019
CLASS PERIOD END: 08/02/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Rigrodsky & Long, P.A. (Wilmington)
  2. RM Law, P.C. (Berwyn)
No Document Title Filing Date
COURT: S.D. New York
DOCKET #: 19-CV-07528
JUDGE: Hon. Judge Colm F. Connolly
DATE FILED: 08/12/2019
CLASS PERIOD START: 06/03/2019
CLASS PERIOD END: 08/12/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Moore Kuehn, PLLC
    30 Wall Street, 8th Floor, Moore Kuehn, PLLC, NY 10005
    212.709.8245 ·
No Document Title Filing Date
—Related District Court Filings Data is not available